AVA6207
Not disclosed (difficult to treat cancers)
PreclinicalDual payload system; clinical candidate selection anticipated late 2026
Key Facts
Indication
Not disclosed (difficult to treat cancers)
Phase
Preclinical
Status
Dual payload system; clinical candidate selection anticipated late 2026
Company
About Avacta Group
Avacta Therapeutics is challenging conventional cancer drug delivery with its proprietary pre|CISION® platform, which aims to widen the therapeutic index of potent oncology drugs by ensuring release occurs specifically in the tumor microenvironment. The company's lead asset, faridoxorubicin (AVA6000), has demonstrated improved safety and tumor-specific drug concentration in Phase 1 trials, while its second program, AVA6103, incorporates a sustained-release mechanism. Avacta is advancing a pipeline of peptide and Affimer® drug conjugates, with a vision to expand the utility of existing cancer therapies across approximately 90% of solid tumors.
View full company profile